ContactCredit ReportFinancialsPeopleOwnershipLatest ActivityMutual CompaniesDocumentsRepayment History

Graegis Pharmaceuticals Limited

Graegis Pharmaceuticals Limited is an active company incorporated on 14 October 2021 with the registered office located in . Graegis Pharmaceuticals Limited was registered 4 years ago.
Status
Active
Active since incorporation
Company No
13680871
Private limited company
Age
4 years
Incorporated 14 October 2021
Size
Micro
Turnover is under £1M
Under 10 employees
Confirmation
Submitted
Dated 13 October 2025 (1 month ago)
Next confirmation dated 13 October 2026
Due by 27 October 2026 (11 months remaining)
Last change occurred 1 year 1 month ago
Accounts
Submitted
For period 1 Jan31 Dec 2024 (1 year)
Accounts type is Small
Next accounts for period 31 December 2025
Due by 30 September 2026 (10 months remaining)
Address
C/O The Cambridge Partnership The Dorothy Hodgkin Building
Babraham Research Campus
Cambridge
CB22 3FH
United Kingdom
Same address since incorporation
Telephone
Unreported
Email
Unreported
Website
Unreported
People
Officers
2
Shareholders
1
Controllers (PSC)
1
Director • French • Lives in Switzerland • Born in Nov 1970
PSC
Shareholders, PSCs & Group Structure
See who truly controls a company with full PSC, Shareholder, and Group Structure exploration
Mutual Companies
Methuselah Health UK Limited
The Cambridge Partnership Limited is a mutual person.
Active
Pandeia Therapeutics Limited
The Cambridge Partnership Limited is a mutual person.
Active
Elements Squared Limited
The Cambridge Partnership Limited is a mutual person.
Active
Ampkine Limited
The Cambridge Partnership Limited is a mutual person.
Active
S Xpress Bio Limited
The Cambridge Partnership Limited is a mutual person.
Active
Imhotex Limited
The Cambridge Partnership Limited is a mutual person.
Active
SDS Therapeutics Limited
The Cambridge Partnership Limited is a mutual person.
Active
Perfect Balance Bio Limited
The Cambridge Partnership Limited is a mutual person.
Active
Financials
Net Assets, Total Assets & Total Liabilities (2022–2024)
Period Ended
31 Dec 2024
For period 31 Dec31 Dec 2024
Traded for 12 months
Cash in Bank
£2.94M
Decreased by £2.11M (-42%)
Turnover
Unreported
Same as previous period
Employees
Unreported
Same as previous period
Total Assets
£3.03M
Decreased by £2.06M (-40%)
Total Liabilities
-£395.35K
Increased by £79.84K (+25%)
Net Assets
£2.64M
Decreased by £2.14M (-45%)
Debt Ratio (%)
13%
Increased by 6.83% (+110%)
Latest Activity
Confirmation Submitted
1 Month Ago on 17 Oct 2025
Small Accounts Submitted
5 Months Ago on 11 Jun 2025
Confirmation Submitted
1 Year 1 Month Ago on 15 Oct 2024
Small Accounts Submitted
1 Year 1 Month Ago on 9 Oct 2024
Notification of PSC Statement
2 Years Ago on 6 Nov 2023
Accounting Period Extended
2 Years Ago on 27 Oct 2023
Medicxi Iii Lp (PSC) Resigned
2 Years 1 Month Ago on 14 Oct 2023
Francesco De Rubertis Resigned
2 Years 1 Month Ago on 14 Oct 2023
Christian Bloy Resigned
2 Years 1 Month Ago on 14 Oct 2023
Clevexel Pharma (PSC) Appointed
2 Years 3 Months Ago on 1 Aug 2023
Get Credit Report
Discover Graegis Pharmaceuticals Limited's Credit Score, how much credit you can offer them, and how likely they are to repay you
Documents
Confirmation statement made on 13 October 2025 with no updates
Submitted on 17 Oct 2025
Accounts for a small company made up to 31 December 2024
Submitted on 11 Jun 2025
Confirmation statement made on 13 October 2024 with updates
Submitted on 15 Oct 2024
Accounts for a small company made up to 31 December 2023
Submitted on 9 Oct 2024
Resolutions
Submitted on 6 Nov 2023
Notification of a person with significant control statement
Submitted on 6 Nov 2023
Memorandum and Articles of Association
Submitted on 6 Nov 2023
Change of share class name or designation
Submitted on 6 Nov 2023
Change of share class name or designation
Submitted on 6 Nov 2023
Cessation of Clevexel Pharma as a person with significant control on 14 October 2023
Submitted on 27 Oct 2023
Repayment History
Understand how businesses repay their debts and see how they're performing year‐on‐year